A low molecular weight polysaccharide isolated from Agaricus blazei suppresses tumor growth and angiogenesis in vivo.
A low molecular weight polysaccharide isolated from Agaricus blazei suppresses tumor growth and angiogenesis in vivo.
复制标题
DOI：
10.3892/or_00000201
复制
发表时间：
2009
期刊：
影响因子：
4.2
通讯作者：
Y. Niu;Jicheng Liu;Xuemei Zhao;X. Wu
中科院分区：
文献类型：
--
作者：
Y. Niu;Jicheng Liu;Xuemei Zhao;X. Wu
研究表明，巴西蘑菇低分子量多糖提取物是潜在的抗肿瘤药物或肿瘤治疗的辅助剂。本文研究了从巴西蘑菇中分离得到的低分子量多糖LMPAB的抗肿瘤活性及其分子机制。使用小鼠肉瘤180（S180）异种移植模型检查LMPAB的抗肿瘤作用。采用鸡胚绒毛尿囊膜（CAM）血管生成和Matrigel诱导的体内血管生成模型，观察LMPAB的抗血管生成作用。血管内皮生长因子（VEGF）的mRNA和蛋白水平进行了评估，采用实时逆转录聚合酶链反应，免疫组织化学和酶联免疫吸附试验。以50、100和200 mg/kg/天剂量给予LMPAB 2周后，S180异种移植模型中的肿瘤抑制率分别为9.7%、23.9%和33.0%。LMPAB还抑制CAM模型中的血管生成和C57 BL/6小鼠中Matrigel诱导的新血管形成。LMPAB治疗后，肿瘤组织中VEGF的mRNA和蛋白水平均显著下调。此外，在小鼠中还观察到血清VEGF水平的显著下调。提示LMPAB可能是一种有前途的肿瘤治疗药物，其抗肿瘤和抗血管生成作用可能与下调VEGF有关。
Previous studies indicated that the low molecular weight polysaccharide extracts from Agaricus blazei are potential antitumor agents or adjuvant in tumor treatment. In this study, we investigated the antitumor activity of LMPAB, a low molecular weight polysaccharide isolated from Agaricus blazei, and the molecular mechanisms of its antitumor activity. The antitumor effect of LMPAB was examined using mouse sarcoma 180 (S180) xenograft models. Antiangiogenic effect of LMPAB was determined by chicken embryo chorioallantoic membrane (CAM) angiogenesis and Matrigel-induced neovascularization in vivo models. The mRNA and protein levels of vascular endothelial growth factor (VEGF) were assessed using real-time reverse transcription-polymerase chain reaction, immunohistochemistry, and enzyme-linked immunosorbent assays. Tumor inhibitory rates in the S180 xenograft models were 9.7, 23.9, and 33.0%, respectively, after administration of LMPAB at dose of 50, 100, and 200 mg/kg/day for 2 weeks. LMPAB also inhibited angiogenesis in the CAM model and Matrigel-induced neovascularization in C57BL/6 mice. The mRNA and protein levels of VEGF in tumor tissues were significantly down-regulated in the BALB/c mice received LMPAB treatment. Furthermore, significant down-regulation of serum VEGF levels was also observed in the mice. Our data suggest that LMPAB might be a promising agent for tumor therapy, and the antitumor and antiangiogenic effects of LMPAB may be related with down-regulation of VEGF.